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Introduction
Evidence has accumulated suggesting
that regular cannabis use is associated with
psychotic symptoms and disorders in the
general population [1,2] and elevated
among incident cases of psychosis [3,4].
In this paper, we present the arguments for,
and implications of, considering cannabis
use as a risk factor for psychosis in the 2005
Global Burden of Disease (GBD) project.
Examining Risk Factors for
Disease Burden
Governments, policymakers, and funders
need information on the comparative pop-
ulation health impact of different diseases
and risk factors when making decisions
about where to focus policy, services, and
research. This field was revolutionised when
the World Bank provided estimates using
the disability-adjusted life year (DALY) [5].
This measure combined measures of prema-
ture mortality (years of life lost [YLL]) and
morbidity (years lived with disability [YLD])
in order to estimate GBD. Estimates of
burden attributable to various risk factors—
‘‘comparative risk assessment’’ (CRA) exer-
cises [6]—are particularly important because
they quantify and allow comparison of the
extent to which reduction or removal of
exposure to risk factors would reduce disease
burden by using a measure of estimated
Population Attributable Risks (PAR). The
GBD uses fairly standard criteria to evaluate
‘‘risk factors’’, in line with Bradford Hill’s [7]
oft-quoted criteria (Box 1).
Evidence on the Association between
Cannabis Use and Psychosis
In the previous global CRA, cannabis
use was not included as a risk factor for
any disease because of concerns about
the quality of the evidence [8]. In the
intervening years there has been a steady
increase in the number and quality of
research studies that have been conducted
exploring the links between cannabis use
and psychosis. Overall, these studies
indicate that chance is an unlikely expla-
nation of their association [9–11]. Recent
reviews of prospective general population
studies of associations between cannabis
use and later psychosis (Table 1) [10,11]
concluded that although control for con-
founding reduced the size of the associa-
tion, there was an increased risk of
psychotic outcomes in individuals who
used cannabis, with the greatest risk
among those who used cannabis most
frequently.
It is useful to distinguish two primary
ways in which cannabis use could be a
‘‘cause’’ of psychosis [12]. The strongest
form of causal link is that heavy cannabis
use causes a psychosis that would not
otherwise have occurred. A second hy-
pothesis is that cannabis use is a contrib-
utory cause: it might precipitate psychosis
in vulnerable individuals—that it is one
factor among many (including genetic
predisposition and other unknown causes)
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Summary
N Comparative risk assessments estimate the proportion of a disease that can be
attributed to a particular risk exposure and are important guides for health
planning.
N In observational studies, there has been consistent evidence that cannabis use
is associated with an increased risk of schizophrenia and more generally,
psychosis.
N There is debate about whether such observational evidence is sufficient to infer
that cannabis use is a contributory cause of psychosis.
N Given the controversy, should the comparative risk assessment in the current
revision of the Global Burden of Disease (GBD) include an attribution of
psychosis to cannabis use?
N We argue that the risk assessment should be included because the evidence is
as good as that for many other risk factors included in the GBD, psychotic
disorders are associated with substantial unavertable disability, and cannabis
use is a potentially preventable exposure.
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disorders.
The evidence suggests that it is more
likely that cannabis use precipitates psy-
chosis in vulnerable persons, which is
consistent with other lines of evidence
suggesting that there is a complex constel-
lation of factors leading to the develop-
ment of psychosis (the stress-diathesis
model of schizophrenia) and with studies
suggesting that gene-environment interac-
tions may provide some explanation of the
association [13]. It is also consistent with
conflicting evidence to date on whether
changes in cannabis use have been
associated with changes in the incidence
of psychotic disorders in the general
population [14–16].
There is also some evidence that
cannabis use is associated with increased
likelihood of relapse to psychosis among
those who have developed a psychotic
disorder [17], although the quality of
control for confounding in these studies
is poor [17]. In some studies cannabis use
has also been associated with a younger
age of onset of psychosis [18], although
control for confounding variables in these
has also been poor.
Is the Association Biologically
Plausible?
The principal psychoactive ingredient
of cannabis is delta-9-tetrahydrocannabi-
nol (THC), which acts upon a specific
cannabinoid receptor (CB1) in the brain
[19]. Although historically the dopaminer-
gic system has been considered to play an
important role in psychotic disorders [20],
there is increasing evidence that the
cannabinoid system may also be involved
[21]. Some studies have used animal
models to explore the impact of THC
and related compounds on brain function
[21–24]. These results are also stimulating
new preclinical research aimed at describ-
ing neurobiological mechanisms of action
linking cannabis and outcomes of interest
to schizophrenia [22]. Rodent models are
being developed to examine the impact of
THC exposure on pathways implicated in
clinical schizophrenia [21].
What Do We Mean by
‘‘Psychosis’’?
Transient cannabis-induced psy-
chotic symptoms. It is possible that
cannabis use might temporarily trigger
some symptoms of psychosis among some
users. Such symptoms are clinically (and
significantly) distinct from a psychotic
disorder such as schizophrenia.
Other drugs such as amphetamine have
also been shown to have the potential to
trigger psychotic symptoms among some
users [25]. Double-blind provocation stud-
ies using intravenous THC and related
compounds in healthy controls are pro-
viding insights into the neurobiological
correlates of cannabis-related transient
psychotic symptoms and neuro-cognitive
impairments [26–29].
Several cross-sectional studies have ex-
amined the relationship between cannabis
use and self-reported psychotic experienc-
es or psychotic symptoms in the general
population. All have found that cannabis
use (or cannabis use disorders) were more
common among people reporting such
experiences; and these associations persist-
ed after controlling for other variables
[1,2,12,30]. Although these findings pro-
vide important clues to the mechanisms of
action linking cannabis use and persistent
psychotic symptoms and/or clinical diag-
noses, these outcomes are less of a concern
for the research community.
It is not always clear whether the
psychotic symptoms endorsed in studies
assessing the relationship between canna-
bis use and ‘‘psychosis’’ occurred only in
the context of cannabis intoxication, or
whether the symptoms were a more distal
outcome of previous cannabis use. For
example, the Fergusson et al. study [31]
assessed the relationship between psychot-
ic symptoms in the past month with
cannabis use in the past year. It remains
possible that the psychotic symptoms
endorsed may have been experienced only
while intoxicated. The instruments used to
measure psychotic outcomes in the Ar-
senault et al. [32], Henquet et al. [33], and
van Os et al. [34] studies contain instruc-
Box 1. Risk Factor Definitions in the 2005 GBD Project [66]
The GBD defines risks according to the following considerations:
N Risk factors should be potentially modifiable;
N Risks should be assessed irrespective of place in a causal chain or scientific
discipline that has traditionally analysed the risk factor, as long as evidence of
causal effect can be established;
N Risks are defined to be not too broad (e.g., diet or environment as a whole) or
too narrow (e.g., every single fruit and vegetable or every toxicant in tobacco
smoke) with a relatively specific definition of risk factor exposure;
N Protective as well as hazardous factors are considered. However, the absence of
a specific intervention should not be assessed as a risk factor, but rather in
measurement of intervention coverage and effectiveness; and
N There exist sufficient data on risk factor exposure and risk-factor disease
relationships.
Table 1. Summary of two systematic reviews investigating cannabis use as a risk factor for psychosis.
Study Details Adjusted Pooled Estimate (95% CI)
Moore et al. [11] Searched Medline, Embase, CINAHL, PsycINFO, ISI Web of Knowledge, ISI Proceedings, ZETOC, BIOSIS,
LILACS, and MEDCARIB from their inception to September, 2006; searched reference lists of studies
selected for inclusion; contacted experts. Studies were included if longitudinal and population based.
Seven studies were included (some multiple papers). Data extraction and quality assessment were
done independently and in duplicate.
Ever use: 1.41 (1.20–1.65)
‘‘Heavy’’ use: 2.09 (1.54–2.84)
Arsenault et al. [12] The research strategies used were: computerized Medline and PsycLIT searches; cross-referencing of
original studies; contact with other researchers in the field. Studies that included a well-defined sample
drawn from population-based registers or cohorts and used prospective measures of cannabis use and
adult psychosis.
2.34 (1.69–2.95)
doi:10.1371/journal.pmed.1000133.t001
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that only occur in the context of intoxica-
tion. Further, the authors of the Swedish
conscript study [35] maintain that it is
unlikely that substance-induced intoxica-
tion would have been misdiagnosed as
schizophrenia. We turn now to the
evidence relating to more persistent symp-
toms or disorders.
Schizophrenia and other psychotic
disorders. In case-control studies
[36,37], patients with schizophrenia are
more likely to use cannabis than other
psychiatric patients or normal controls
[38]. The prevalence of use in patients
with schizophrenia has varied between
studies but it is generally higher than rates
in the general population [38,39].
Cross-sectional community surveys of
psychiatric disorders have also document-
ed higher rates of substance use disorders
among persons with schizophrenia [40].
Nearly half of the patients identified with
schizophrenia in the US ECA study had a
diagnosis of substance abuse or depen-
dence (28% for an illicit drug disorder)
[41,42]. In an Australian population-
based survey, 11.5% of those who report-
ed that they had been diagnosed with
schizophrenia met ICD-10 criteria for a
cannabis use disorder in the past 12 mo,
and 21.2% met criteria for an alcohol use
disorder. After adjusting for confounding
variables, those who met criteria for
cannabis dependence were 2.9 times more
likely to report that they had been
diagnosed with schizophrenia than those
who did not [1].
The first evidence that cannabis use
may precipitate schizophrenia came from
a 15-y prospective study of cannabis use
and schizophrenia in 50,465 Swedish
conscripts [43]. This study investigated
the relationship between self-reported
cannabis use at age 18 y and the risk of
being diagnosed with schizophrenia in the
Swedish psychiatric case register during
the next 15 y. Those who had tried
cannabis by age 18 y were 2.4 times more
likely to receive a diagnosis of schizophre-
nia than those who had not. The risk of a
diagnosis of schizophrenia was related to
cannabis use in a dose-response way to the
number of times cannabis had been used
by age 18. Compared to those who had
not used cannabis, the risk of developing
schizophrenia was 1.3 times higher for
those who had used cannabis one to ten
times, three times higher for those who
had used cannabis between one and 50
times, and six times higher for those who
had used cannabis more than 50 times.
These results remained after statistical
adjustment for two variables that were
related to the risk of developing schizo-
phrenia (personal history of psychiatric
disorder and parental divorce).
A number of longitudinal studies have
since been reported that have all support-
ed the findings of the Andreassen et al.
study. Zammit et al. reported a follow up
of the Swedish cohort study, reporting on
risk over a 27-y follow up that covers most
of the risk period for the onset of psychotic
disorders in a cohort that was first studied
when 18–20 y old [35]. This study im-
proved on the earlier study in a number of
ways. The psychiatric register provided
more complete coverage of all cases
diagnosed with schizophrenia; there was
better statistical control of a larger number
of potential confounding variables, includ-
ing other drug use, IQ, known risk factors
for schizophrenia, and social integration;
the study distinguished between cases that
occurred in the first 5 y of the study period
and those that occurred more than 5 y
afterwards in order to look at the possible
role of a syndrome; and the study
undertook separate analyses in those who
only reported using cannabis at the initial
assessment.
Zammit et al. [35] also found cannabis
use at baseline predicted an increased risk
of schizophrenia during the follow-up
period. There was a dose-response rela-
tionship with frequency of use, which
persisted after statistical control for con-
founders, including a history of psychiatric
symptoms at baseline. The same relation-
ships were observed in the subset of the
sample who only reported cannabis use at
baseline and among cases diagnosed in the
first 5 y after assessment and for the
subsequent 22 y.
Zammit et al.’s findings were consistent
with those of a study conducted by Van
Os and colleagues [34]. This was a 3-y
longitudinal study of the relationship
between self-reported cannabis use and
psychosis in a community sample of 4,848
people in the Netherlands. Participants
were assessed at baseline on cannabis and
other drug use. Psychotic symptoms were
assessed using a computerised diagnostic
interview. A diagnosis of psychosis was
validated in positive cases by a diagnostic
telephone interview with a psychiatrist or
psychologist. A consensus clinical judge-
ment was made on the basis of the
interview material as to whether individ-
uals had a psychotic disorder for which
they were in need of psychiatric care.
Van Os et al. replicated and extended
the findings of the Swedish cohort in a
number of important ways. First, cannabis
use at baseline predicted an increased risk
of psychotic symptoms during the follow-
up period in individuals who had not
reported psychiatric symptoms at baseline.
Second, there was a dose-response rela-
tionship between frequency of cannabis
use at baseline and risk of psychotic
symptoms during the follow-up period.
Third, the relationship between cannabis
use and psychotic symptoms persisted
when they statistically controlled for the
effects of other drug use. Fourth, the
relationship between cannabis use and
psychotic symptoms was stronger for cases
with more severe psychotic symptoms that
were adjudged to need psychiatric care.
Fifth, those who reported any psychotic
symptoms at baseline were more likely to
develop schizophrenia if they used canna-
bis than were individuals who were not so
vulnerable.
A study by Henquet et al. [33] replicat-
ed the Swedish and Dutch studies in a 4-y
follow up of a cohort of 2,437 adolescents
and young adults between 1995 and 1999
in Munich. Their participants were assess-
ed at baseline on cannabis use and
psychotic symptoms using a questionnaire.
Psychotic symptoms were assessed in early
adulthood using the Composite Interna-
tional Diagnostic Interview. They found a
dose-response relationship between self-
reported cannabis use at baseline and the
likelihood of reporting psychotic symp-
toms. As in the Dutch cohort, young
people who reported psychotic symptoms
at baseline were much more likely to
experience psychotic symptoms at follow
up if they used cannabis than were peers
who did not have such a history.
Arseneault et al. reported a prospective
study of the relationship between adoles-
cent cannabis use and psychosis in young
adults in a New Zealand birth cohort
(n=759). Participants were assessed inten-
sively on risk factors for psychotic symp-
toms and disorders since birth [32], and
psychotic disorders were conservatively
assessed according to DSM-IV diagnostic
criteria, with corroborative reports from
family members or friends on social
adjustment. They assessed psychotic
symptoms at age 11 y before onset of
cannabis use and distinguished between
early and late onset of cannabis use. They
also examined the specificity of the
association between cannabis use and
psychosis by conducting analyses of the
effects of: (1) other drug use on psychotic
symptoms and disorders; and (2) cannabis
use on depressive disorders.
Arseneault et al. found a relationship
between cannabis use by age 15 y and an
increased risk of schizophreniform disor-
der by age 26 y. Controlling for other
drug use did not affect the relationship.
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significant after adjustment for reporting
psychotic symptoms at age 11 y, which
probably reflected the small number of
psychotic disorders observed in the sam-
ple. The small number of cases also limited
the ability of the study to examine
predictors of psychotic disorders at age
26 y. The measurement of cannabis and
other drug use was crude (viz, none, 1–2
times, and 3 or more times), although this
was more likely to work against finding
relationships.
There was also specificity in the effects
of cannabis on schizophreniform disorder:
there was no relationship between other
drug use and psychotic disorders, and no
relationship between cannabis use and
depression. There was also an interaction
between psychosis risk and age of onset of
cannabis use, with earlier onset being
more strongly related to psychosis. There
was also the suggestion of an interaction
between cannabis use and vulnerability,
with a higher risk of psychosis among
cannabis users who reported psychotic
symptoms at age 11 y.
Caspi and colleagues subsequently used
the cohort to examine an interaction
between cannabis use and a functional
polymorphism of the COMT gene that
codes for dopamine in their effects on the
risk of psychosis [44]. They found that the
25% of the cohort who were homozygous
for the polymorphism and used cannabis
were 10.9 times more likely to have
developed a schizophreniform disorder
than peers with the same polymorphism
who did not use cannabis. In the absence
of this polymorphism, young adults who
used cannabis were not at any increased
risk of psychosis.
Apart from clinical diagnoses, several
longitudinal studies have also examined
the relationship between cannabis use and
subclinical (or isolated) psychotic symp-
toms. Fergusson, Horwood, and Swain-
Campbell have reported a longitudinal
study of the relationship between canna-
bis dependence at age 18 y and the
number of psychotic symptoms reported
at age 21 y in the Christchurch birth
cohort in New Zealand [45]. They
assessed cannabis dependence using
DSM-IV criteria and psychotic symptoms
were assessed by ten items from the SCL-
90. Because this was a birth cohort that
had been assessed throughout childhood
and adolescence Fergusson et al. were
able to adjust for a large number of
potential confounding variables, includ-
ing self-reported psychotic symptoms at
the previous assessment, other drug use,
and other psychiatric disorders. They
found that cannabis dependence at age
18 y predicted an increased risk of
psychotic symptoms at age 21 y (relative
risk [RR] of 2.3). This association was
smaller but still significant after adjust-
ment for potential confounders (RR of
1.8). More recently, Fergusson and col-
leagues examined the association between
cannabis and psychotic symptoms until
age 25 y with the same cohort of young
adults, using a more sophisticated struc-
tural equations modelling design that
accounted for both observed and non-
observed confounding factors [31]. As
with their earlier study, they concluded
that the association between cannabis and
psychosis did not appear to be explained
by confounding factors, and that the
direction of the association appeared to
be from cannabis use to symptoms of
psychosis rather than vice versa.
One study of high risk young people has
failed to report an association between
cannabis use and psychosis risk. This study
identified 100 young people at ‘‘ultra
high’’ risk for psychosis [46] because of
family history or prodromal symptoms of
psychosis (on the basis of one or more of
the following: schizophrenia in a first
degree relative; the presence of attenuated
psychotic symptoms; or a brief limited
psychosis) in whom 18% reported symp-
toms of cannabis dependence in the past
year. They assessed whether cannabis
users were more likely to develop psychosis
in the following year, but did not find any
association, regardless of the frequency of
cannabis use.
Increasingly, researchers in the field of
psychosis are examining the concept of
psychotic spectrum features as risk factors
for psychosis [47]. Recent work has found
that these symptoms are common in the
general population distribution and can
persist over a 20-y period. Two major
trajectories have been identified: persistent
‘‘schizophrenic nuclear symptoms’’ (which
resemble psychosis) and persistent ‘‘schizo-
typal symptoms’’ (more closely resembling
schizotypal personality disorder) [47].
Cannabis use during adolescence has been
found to be associated with ‘‘high load’’
schizophrenia nuclear symptoms during
adulthood—but not so for the schizotypal
symptom cluster. More frequent cannabis
use was more strongly associated with
persistent high load symptoms for the
entire follow-up period. These findings
suggest that there may be different aetio-
logical dimensions for these two symptom
dimensions, with an interaction between
biological vulnerability and unique psy-
chosocial risk factors for each symptom
cluster; limitations of the study included
the small number of cases, the use of open
ended interviews, and the use of multiple
analyses.
The Effects of Varying Outcome
Measures
There are several major criticisms of the
above evidence. The first concerns the
varying outcome measures that different
studies have used. These include ‘‘psycho-
sis,’’ psychotic symptoms, and schizo-
phreniform disorders diagnosed using
psychiatric interviews and psychiatric case
registers.
How should this affect confidence in the
study findings? We suggest that they are
less of an issue than they first appear. First,
as noted above, there is a growing
recognition that psychotic-like experiences
can provide valuable clues with respect to
underlying neurobiological mechanisms
and shared risk factors for psychotic
disorders. Categorical diagnostic criteria
do not provide the final word on these
disorders. The exploration of psychotic
symptoms (or psychotic-like experiences)
has become a very fertile area of research
[48]. These studies have generally shown
that persons with these symptoms have an
elevated risk of being formally diagnosed
with a psychosis later in life [49]. In the
section below, we review recent data on
this issue.
Second, most studies of the association
(with sample sizes of 1,000–4,000) have
very low statistical power for detecting any
effect that cannabis use has on the risk of
diagnosed psychotic disorders. More prev-
alent outcomes, such as subclinical psy-
chotic symptoms, have provided greater
power to examine associations.
Third, we would also argue that the
persistence of a correlation between can-
nabis use and these variously measured
outcomes is more suggestive of a robust
relationship than the contrary. This is
because the use of differing measures of
varying predictive validity may be expect-
ed to attenuate rather than positively bias
measures of association between cannabis
use and psychosis. Finally, the Swedish
and Dutch studies that have investigated
diagnosed psychotic disorders have found
the same associations as studies of psy-
chotic symptoms.
Temporal Relationship
Many prospective studies share the
weakness that they cannot precisely specify
the timing of first cannabis use and the
onset of psychotic symptoms. Participants
have usually been assessed once a year or
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report their cannabis use during the past
year(s). This assessment has often been in
terms of the total number of times
cannabis was used, or the number of times
on average that cannabis was used each
week or month. Nonetheless, there are
multiple prospective studies of representa-
tive samples of the general population, all
of which show that cannabis use at one
point in time is associated with psychotic
symptoms at a later one, even after using a
range of controls for confounding and
various statistical approaches to analysis.
Studies undertaking more temporally
fine-grained measurements have provid-
ed results consistent with these cruder
measurements. A French study using an
experience sampling method [50] found a
positive association between self-reported
cannabis use and unusual perceptions,
and a negative association with hostility,
over periods of hours. In those with pre-
existing psychotic symptoms, cannabis
use was more strongly associated with
strange impressions and unusual percep-
tions, and its use did not decrease feelings
of hostility [50].
Another study, involving monthly as-
sessment of psychotic symptoms and
cannabis use over 10 mo among persons
with psychotic disorders, similarly found
that more frequent cannabis use in one
month was related to increases in psychot-
ic symptoms a month later [51]. These
lines of evidence suggest that the temporal
relationship criterion is satisfied.
Has the Evidence Base Been
Affected by Publication Bias?
Publication bias is a potentially more
serious concern: If negative results have
been withheld from publication then the
consistent positive results would be far less
impressive than they seem from the
published systematic reviews [52]. This
possibility was investigated by the authors
of one systematic review who surveyed
researchers in the area asking about any
studies with negative results that had not
been published [10]. They concluded that
this was not a serious issue in this instance.
Is There Residual Uncontrolled
Confounding?
The most difficult task in drawing causal
inferences from observational studies is
excluding the possibility that the relation-
ship between cannabis use and psychosis is
due to other uncontrolled factors (e.g.,
other drug use, genetic predisposition to
develop schizophrenia and use cannabis, or
self-medication). This has led some to
object to calculation of estimates of popu-
lation attributable risk (PAR) because the
adjusted estimates are modest (typically
around 2–3), and so open to the alternative
explanation of uncontrolled confounding.
For example, some have suggested that the
propensity to take risks and engage in
socially disapproved behaviour may be a
common cause of cannabis use and psy-
chotic symptoms [53]. Fergusson et al.
attempted to address these criticisms by
using fixed effects regression models to
adjust forall unmeasured confounders[31].
Some may argue that a causal inference
demands evidence that the cessation of
cannabis use reduces these risks, as the
evidence of risk reversal on cessation in the
British doctors’ study strengthened the case
for a causal relationship between cigarette
smoking andlung cancerandotherdiseases
[54]. However, even this evidence did not
persuade some sceptics in the case of
tobacco use, with some arguing (uncon-
vincingly) that those at lowest risk of these
adverse health outcomes found it easier to
quit [55]. What was probably more impor-
tant was the consilience of a complex array
of different types of evidence that con-
vinced most public health officials that
cigarette smoking caused these diseases
[56]. In recent years, the range of method-
ologies used to investigate the association
between cannabis use and psychosis has
increased and there appears to be a similar
convergence of evidence that the associa-
tion between the two is causal.
It is difficult to see more conclusive
evidence being produced for cannabis as a
contributory cause of psychosis, or for the
results of such studies to be as convincing
as the evidence from cigarette smoking.
This is because: the relationship between
cannabis and psychosis is not as strong as
that between smoking and lung cancer; the
prevalence of cannabis use is so much
lower than that for smoking; and the
outcomes of psychosis are not as easy to
study as mortality was in the Doll and Hill
follow up of the British doctors. How then
can we resolve the uncertainty that
remains?
Epidemiology is an imprecise science,
and recent experience has taught us to be
cautious in making causal inferences from
observational studies [57,58]. With respect
to cannabis, the findings from prospective
longitudinal studies may still be vulnerable
to residual confounding. The best way to
deal with both known and unknown
confounding from interventions (e.g.,
HRT) is to conduct randomised controlled
trials to explore the impact of an exposure
on the health outcome of interest. Clearly,
this strategy cannot be used to explore the
association between cannabis and psycho-
sis. The use of twin or sibling-pair analyses
can reduce unmeasured residual con-
founding to a certain extent [59], but
these studies will still be vulnerable to
criticisms of incomplete control for con-
founding. We have no choice then but to
make cautious inferences about the role of
cannabis in psychosis on the basis of
observational studies.
The Importance of Population
Attributable Risk
Calculation of a PAR is important to
place the magnitude of the cannabis and
psychosis association in a population
health context. Arsenault et al. [11]
concluded that elimination of all cannabis
use would reduce the incidence of schizo-
phrenia in the United Kingdom by
approximately 8%, assuming that the
relationship was ‘‘causal’’ in the sense that
schizophrenia would not have occurred in
the absence of cannabis use; Zammit et al.
[35] similarly estimated that 13% of
schizophrenia cases in Sweden were at-
tributable to cannabis use.
Nonetheless, these PAR estimates must
be heavily qualified. Risk models related to
complex and heterogeneous syndromes
like schizophrenia will never be fully
specified. Further, standard PAR estimates
cannot account for the possibility that
cannabis has brought forward the age of
onset in an individual who would have
otherwise developed the illness at a later
age without exposure to cannabis [60].
Notwithstanding these limitations, a PAR
has utility from a public health perspective
in that it combines information about
exposure-risk effect size and the preva-
lence of the exposure and helps the
research community to prioritise public
health interventions, a central aim of the
GBD exercise. Because it is unlikely that
we will ever have fully specified models,
we should use PARs cautiously and
conduct sensitivity analyses to assess the
effects of uncertainty in our estimates.
Is It Premature to Suggest that
Cannabis Is a Risk Factor for
Psychosis?
Some commentators may well argue that
it is premature to conclude that the
relationships between cannabis use and
psychosis are causal, which raises the
question of what the standard of proof
should be causal inference. Some may
argue for ‘‘proof beyond reasonable
doubt,’’ the standard implicitly used in the
PLoS Medicine | www.plosmedicine.org 5 September 2009 | Volume 6 | Issue 9 | e1000133last iteration of the GBD [8]. It is rare,
however, to meet this standard of proof for
noncommunicable diseases other than
smoking-related diseases. What has
changed since the last iteration of the
GBD? The broad approach to all risk
factors has been to set the standard of proof
at ‘‘more likely than not,’’ rather than
‘‘beyond reasonable doubt.’’ If the latter
was the standard of proof, then no adverse
health consequences of cannabis would be
considered apart from dependence.
If we had treatments that resulted in
complete, immediate, and sustained remis-
sion for all individuals who develop psycho-
sis, then the role of cannabis as an
aetiological agent may attract less attention.
But schizophrenia remains a poorly under-
stood group of disorders. Even our best
treatments are suboptimal [61,62]. In the
absence of better treatments, the most
effective way to reduce the disability associ-
ated with schizophrenia is to prevent its
occurrence when we can [63]. Thus, when
considering potential risk factors for schizo-
phrenia, we argue that candidates that offer
the opportunity for public health interven-
tions should be accorded more attention
(e.g., education about the potential risks of
cannabis use). Even exposures that may
account for a small attributable fraction of
those with the disorder warrant scrutiny.
A Way Forward
Making estimates of the proportion of
psychoses attributable to cannabis will in
effect provide worst case estimates of the
burden of disease (BoD) attributable to
cannabis if the critics are correct that
uncontrolled confounding explains the
relationships between cannabis use and
psychosis. In Australia, for example,
cannabis use was included as a risk factor
in the Australian BoD study, assuming
causal relationships for cannabis depen-
dence, psychosis, suicide, and car crashes
[64]. Even after assuming that these
relationships were causal, cannabis was
not a major contributor to disease burden
in Australia, accounting for 0.2% of all
disease burden, which amounted to 10%
of the total burden attributable to all illicit
drugs [65]. These estimates are important
for public policy purposes, because failure
to make them allows untested estimates to
be offered in public policy debate.
In the GBD project, we are considering
several possible ways in which cannabis
and psychosis may be linked. A range of
estimates will be made as follows: (1) a
model that will assume greater disorder
severity among those using cannabis
regularly who have already developed
the disorder; (2) a model that will assume
the association reflects earlier onset of the
disorder among those who would have
developed it anyway; (3) a model that will
assume reduced remission from schizo-
phrenia once it has developed; and (4) a
model that assumes increased incidence of
schizophrenia.
It is important to consider the conse-
quences of not estimating this risk. There
will be a reduced public health, policy, or
research imperative, since there will be no
estimated burden. If we do attempt to
estimate burden, future work will examine
the accuracy of our estimates and refine
them as evidence accumulates. Debates
may emerge and (hopefully) improvements
made as new evidence supports or chal-
lenges the assumptions made. Estimates
made in GBD 2005 should be seen as a
first step in a process that can and should
be improved with new data and new
insights, including work for future esti-
mates of country and global disease
burden.
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